Search All Tech Briefings


Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available.  Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 7 Results

Title
Intervention Indication Therapeutic Area Year Actions
Abemaciclib in combination with fulvestrant for advanced or metastatic breast cancer after prior endocrine therapy Abemaciclib (LY2835219; Verzenio; CC-115) , Fulvestrant (Faslodex) Breast cancer Breast Cancer 2017 View  |  Download
Alpelisib in Combination with Fulvestrant for Advanced HR Positive, HER2-negative Breast Cancer in Men and Postmenopausal Women Alpelisib (BYL719; Piqray) , Fulvestrant (Faslodex) Breast cancer Breast Cancer 2017 View  |  Download
Capivasertib with fulvestrant for HR+/HER2- locally advanced or metastatic breast cancer Capivasertib , Fulvestrant (Faslodex) Breast cancer Breast Cancer 2023 View  |  Download
Inavolisib with palbociclib and fulvestrant for treating HR+/HER2-, PIK3CA mutated locally advanced or metastatic breast cancer Fulvestrant (Faslodex) , Inavolisib (GDC 0077;RG 6114) , Palbociclib (Ibrance; PD-0332991) Breast cancer Breast Cancer 2024 View  |  Download
Ribociclib (Kisqali) and fulvestrant for advanced HR positive, HER2‐negative breast cancer in postmenopausal women, first or second line Fulvestrant (Faslodex) , Ribociclib (Kisqali; LEE-011; ribociclib succinate) Breast cancer Breast Cancer 2017 View  |  Download
Ribociclib and Fulvestrant and PI3K Inhibitor (Buparlisib or Alpelisib) for HR Positive, HER2 Negative Postmenopausal Breast Cancer – Second or Third Line Alpelisib (BYL719; Piqray) , Fulvestrant (Faslodex) , Ribociclib (Kisqali; LEE-011; ribociclib succinate) Breast cancer Breast Cancer 2017 View  |  Download
Taselisib in Combination with Fulvestrant for Advanced ER Positive, HER2-negative Breast Cancer – Second Line After Aromatase Inhibitor Therapy Fulvestrant (Faslodex) , Taselisib (GDC-0032; RG-7604) Breast cancer Breast Cancer 2017 View  |  Download
Medicines
Medicine Industry's Gateway to NICE
Support for Industry
Outputs & Publications